TLRY - Tilray, Inc.

Tilray, Inc.

1100 Maughan Road
Nanaimo, BC V9X IJ2
Canada
844-845-7291
http://www.tilray.com

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 657

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Brendan Kennedy	Chairman, Pres & CEO	850k	N/A	1972
Mr. Mark Castaneda	CFO & Treasurer	506k	N/A	1965
Mr. Edward Wood Pastorius Jr.	Chief Revenue Officer	433.2k	N/A	1968
Mr. Greg Christopher	Exec. VP of Operations	N/A	N/A	N/A
Ms. Dara Redler	Gen. Counsel & Corp. Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, and compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, the United Kingdom, the United States, and South Africa. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.

Corporate Governance

Tilray, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.